The Raptiva Pregnancy Registry is a prospective observational study established to obtain data on pregnancy outcomes of women who are exposed to Raptiva.

Genders Eligible for Study:  Female

Criteria

• Any patient who has used Raptiva within 6 weeks prior to conception or during her pregnancy may be included in the Registry.
• Enrollment is based on Raptiva exposure, whether inadvertent or deliberate, in relation to pregnancy.
• Enrollment should occur as early as possible during the pregnancy and must occur prior to knowledge of pregnancy outcome.